FI119841B - Substituerade alkanohydroxamsyror och förfarande för sänkande av TNF alfa nivåer - Google Patents
Substituerade alkanohydroxamsyror och förfarande för sänkande av TNF alfa nivåer Download PDFInfo
- Publication number
- FI119841B FI119841B FI20000061A FI20000061A FI119841B FI 119841 B FI119841 B FI 119841B FI 20000061 A FI20000061 A FI 20000061A FI 20000061 A FI20000061 A FI 20000061A FI 119841 B FI119841 B FI 119841B
- Authority
- FI
- Finland
- Prior art keywords
- methoxyphenyl
- ethoxy
- hydroxy
- propionamide
- hydroxamic acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/62—Naphtho [c] pyrroles; Hydrogenated naphtho [c] pyrroles
- C07D209/66—Naphtho [c] pyrroles; Hydrogenated naphtho [c] pyrroles with oxygen atoms in positions 1 and 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Materials Applied To Surfaces To Minimize Adherence Of Mist Or Water (AREA)
- Steroid Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Claims (23)
1. Hydroxamsyraderivat, valt ur en grupp, till vilken hör (a) föreningar med formeln: 5 RV- Λ o J| N-CH* || r2X^-r5' \cnU2n)—c—N —O-R4 R4' vari R1 och R2 tillsammans är, tillsammans med vi-sade kolatomer, vid vilka var och en är bunden, o-10 fenylen eller o-naftylen, vilken är osubstituerad el-ler substituerad med 1-2 substituenter, av vilka var och en oberoende av varandra är vald ur en grupp, till vilken hör nitro, hydroxi, amino, dialkylamino, acyla-mino, en alkylgrupp, som innehäller 1-4 kolatomer, 15 en alkoxigrupp, som innehäller 1 kolatom och halo; R3 är en fenyl, vilken är substituerad med 2 substituenter, vilka är valda ur en grupp, till vilken hör en alkoxigrupp, som innehäller 1-3 kolatomer och en cykloalkoxigrupp, som innehäller 5 kolatomer;
2. Hydroxamsyraderivat enligt patentkrav 1, 30 kännetecknat därav, att föreningen har formeln Rl0X^i~i^-R5 >C„H,„)—C-N
111 N0-R4 R11 vari var och en R4 och R4 är oberoende av varandra väte eller en alkylgrupp, som innehäller 1 kolatom;
3. Hydroxamsyraderivat enligt patentkrav 2, kännetecknat därav, att en av substituen- terna R8, R9, R10 och R11 är amino och de kvarvarande R8, R9, R10 och R11 är väte.
4. Hydroxamsyraderivat enligt patentkrav 2, 20 kännetecknat därav, att en av substituen- terna R8, R9, R10 och R11 är en alkylgrupp, som innehäller 1-4 kolatomer, och de kvarvarande R8, R9, R10 och R11 är väte.
5. Hydroxamsyraderivat enligt patentkrav 2, 25 kännetecknat därav, att R8, R9, R10 och R11 är väte.
5 R5 är —CH2~ eller -CO-; var och en R6 och R7 är oberoende av varandra en alkoxigrupp, som innehäller 1-3 kolatomer eller en cykloalkoxigrupp, som innehäller 5 kolatomer; var och en R8, R9, R10 och R11 är oberoende av 10 varandra väte, nitro, hydroxi, amino, dialkylamino, acylamino, en alkylgrupp, som innehäller 1-4 kolatomer, en alkoxigrupp, som innehäller 1 kolatom och halo; och n är 1.
6. Hydroxamsyraderivat enligt patentkrav 1, kännetecknat därav, att föreningen har for-meln 30 R13 -ju ic JOI \\ ,0H rioS<Y^R5 CH2 C—Ns ,
111 R4 R11 väri R4' är väte eller en alkylgrupp, sorti innehäller 1 kolatom; R5 är C=0 eller CH2; 5 var och en R12 och R13 är oberoende av var- andra en alkoxigrupp, som innehäller 1-3 kolatomer eller en cykloalkoxigrupp, som innehäller 5 kolatomer; och var och en R8, R9, R10 och R11 är oberoende av 10 varandra väte, nitro, hydroxi, amino, dialkylamino, acylamino, en alkylgrupp, som innehäller 1-4 kolatomer, en alkoxigrupp, som innehäller 1 kolatom och halo .
7. Hydroxamsyraderivat enligt patentkrav 6, 15 kännetecknat därav, att var och en R8, R9, R10 och R11 är väte, halo, en alkylgrupp, som innehäller 1-4 kolatomer eller en alkoxigrupp, som innehäller 1 kolatom.
8. Hydroxamsyraderivat enligt patentkrav 6, 20 kännetecknat därav, att en av substituen- terna R8, R9, R10 och R11 är amino, hydroxi eller en alkylgrupp, som innehäller 1-4 kolatomer och de kvar-varande R8, R9, R10 och R11 är väte.
9. Hydroxamsyraderivat enligt patentkrav 1, 25 kännetecknat därav, att nämnda förening är vald ur en grupp tili vilken hör - (3-etoxi-4-metoxifenyl)-N-hydroxi-3-(1-oxoisoindolinyl)propion-amid, 3-(3-etoxi-4-metoxifenyl)-N-hydroxi-3-(4-metyl-ftalimido)propionamid, 3-(3-cyklopentyloxi-4-metoxife-30 nyl)-N-hydroxi-3-ftalimidopropionamid, N-hydroxi-N-me- tyl-3-(3-etoxi-4-metoxifenyl)-3-(1-oxoisoindoli-nyl)propionamid, 3-(3-cyklopentyloxi-4-metoxifenyl)-N-hydroxi-3-(4-metylftalimido)propionamid, 3-(3-etoxi-4-metoxifenyl)-N-hydroxi-3-(1,3-dioxo-2,3-dihydro-lH-5 benzo[f]isoindol-2-yl)-propionamid, 3-(3-etoxi-4-me- toxifenyl)-N-metoxi-3-(1-oxoisoindolinyl)propionamid, N-benzyloxi-3-(3-etoxi-4-metoxifenyl)-3-ftalimidopro-pionamid, N-benzyloxi-3-(3-etoxi-4-metoxifenyl)-3- (3-nitroftalimido)propionamid, N-benzyloxi-3-(3-etoxi-4-10 metoxifenyl)-3-(1-oxoisoindolinyl)propionamid, 3-(3- etoxi-4-metoxifenyl)-N-hydroxi-3-ftalimidopropionamid, N-hydroxi-3-(3,4-dimetoxifenyl)-3-ftalimidopropionamid, 3-(3-etoxi-4-metoxifenyl)-N-hydroxi-3-(3-nitro-ftalimido)propionamid, N-hydroxi-3-{3-(2-propoxi)-4-15 metoxifenyl}-3-ftalimidopropionamid, 3-(3-etoxi-4-me- toxifenyl)-3-(3,6-difluoroftalimido)-N-hydroxipropion-amid, 3-(4-aminoftalimido)-3-(3-etoxi-4-metoxifenyl)-N-hydroxipropionamid, N-hydroxi-3-(3,4-dimetoxifenyl)- 3- (1-oxoisoindolinyl)propionamid, 3-(3-cyklopentyloxi- 20 4-metoxifenyl)-N-hydroxi-3-(1-oxoisoindolinyl)propion amid, N-benzyloxi-3-(3-etoxi-4-metoxi-fenyl)-3-(4-nit-roftalimido)propionamid, 3-(3-amino-ftalimido)-3- (3- etoxi-4-metoxifenyl)-N-hydroxipropionamid, N-hydroxi-N-metyl-3-(3-etoxi-4-metoxifenyl)-3-(1-oxoisoindoli- 25 nyl)propionamid, N-hydroxi-3-(3-(1-metyl)etoxi-4-me- toxifenyl)-3-(1-oxoisoindolinyl)propionamid, 3 — { 3 — etoxi-4-metoxifenyl)-N-hydroxi-3-(3-hydroxiftalimido)-propionamid, 3-(3-etoxi-4-metoxifenyl)-N-hydroxi-3- (4-hydroxiftalimido)propionamid, 3-(3-etoxi-4-metoxife-30 nyl)-N-hydroxi-3-(3-metylftalimido)propionamid, 3-(3- acetamidoftalimido)-3-(3-etoxi-4-metoxifenyl)-N-hyd-roxipropionamid, 3-(4-acetamido-ftalimido)-3-(3-etoxi- 4- metoxifenyl)-N-hydroxipropionamid, 3-(3-etoxi-4-me-toxifenyl)-N-hydroxi-3-(1,3-dioxo-2,3-dihydro-lH- 35 benzo[e]isoindol-2-yl)propionamid, 3-(4-tert-butyl- ftalimido)-3-(3-etoxi-4-metoxifenyl)-N-hydroxipropion-amid, 3-(3,4-dimetoxifenyl)-N-hydroxi-3-(1,3-dioxo- 2,3-dihydro-lH-benzo[e]-isoindol-2-yl)propionamid, 3-(3,4-dimetoxiftalimido)-3-(3-etoxi-4-metoxifenyl)-N-hydroxipropionamid, 3-(3-etoxi-4-metoxifenyyli)-N- hydroxi-3-(3-dimetylaminoftalimido)propionamid och 3-5 (3-etoxi-4-metoxifenyl)-N-hydroxi-3-(3,4-dimetylftalimido) propionamid.
10. Användning av en effektiv mängd hydroxam-syraderivat enligt patentkrav 1 vid framställning av en medioin, vilken sänker oönskade TNFa niväer i dägg- 10 djur.
11. En effektiv mängd hydroxamsyraderivat enligt patentkrav 1 för sänkande av oönskade TNFa niväer i däggdjur.
12. Farmaceutisk sammansattning, kanne- 15 tecknad därav, att sammansättingen innehäller en tillräcklig mängd av ett hydroxamsyraderivat enligt patentkrav 1, vilket givet som en enda eller en fler-faldig dos sänker TNFa niväer i däggdjur tillsammans med en bärare.
13. Farmaceutisk sammansättning, känne- tecknad därav, att sammansättingen innehäller en tillräcklig mängd av ett hydroxamsyraderivat enligt patentkrav 1, vilket givet som en enda eller en fler-faldig dos förhindrar oönskade niväer av bindvävnadens 25 grundämnes metallproteinaser i däggdjur tillsammans med en bärare.
14. Användning av en effektiv mängd hydroxamsyraderivat enligt patentkrav 1 vid framställning av en medicin, vilken förhindrar oönskade niväer av bind- 30 vävnadens grundämnes metallproteinaser i däggdjur.
15. En effektiv mängd hydroxamsyraderivat enligt patentkrav 1 för förhindrande av oönskade niväer av bindvävnadens grundämnes metallproteinaser i dägg-dj ur.
16. Användning av en effektiv mängd av ett hydroxamsyraderivat enligt patentkrav 1 vid framställ-ning av en medicin, vilken medicin sänker oönskade TNFa niväer i däggdjur som en enda dos eller flerfal-dig dos tillsammans med en bärare.
17. Användning av en mängd av ett hydroxamsy-raderivat enligt patentkrav 1 vid framställning av en 5 medioin för att ges som en enda eller en flerfaldig dos för sänkande av TNFa niväer i däggdjur tillsammans med en bärare.
18. Användning av en mängd av ett hydroxamsy-raderivat enligt patentkrav 1 vid framställning av en 10 medioin, för att ges som en enda eller en flerfaldig dos för förhindrande av oönskade niväer av bindvävna- dens grundämnes metallproteinaser i däggdjur tillsammans med en bärare
19. Användning av en effektiv mängd av ett 15 hydroxamsyraderivat enligt patentkrav 1 vid framställ- ning av en medioin, vilken medioin given som en enda eller en flerfaldig dos förhindrar oönskade niväer av bindvävnadens grundämnes metallproteinaser i däggdjur tillsammans med en bärare.
20. Hydroxamsyraderivat enligt patentkrav 1, kännetecknat därav, att * betyder ett ki- ralcentrum, med R-konfiguration.
20 R4 är väte, en alkylgrupp, som innehäller 1 kolatom eller benzylgrupp; R4, är väte eller en alkylgrupp, som innehäller 1 kolatom; R5 är -CH2- eller -CO-; och 25 n är 1; och (b) syra additionssalt av nämnda föreningar, vilka innehäller en kväveatom, vilken kan protonise-ras.
21. Hydroxamsyraderivat enligt patentkrav 1, kännetecknat därav, att * betyder ett ki- 25 ralcentrum med S-konfiguration.
22. Farmaceutisk sammansättning, känne-t e c k n a d därav, att sammansättningen innehäller en effektiv mängd av ett hydroksamsyraderivat enligt patentkrav 1, att användas som medioin för förhindran- 30 de av PDE4 i däggdjur som en enda eller en flerfaldig dos tillsammans med en bärare.
23. Farmaceutisk sammansättning, känne-t e c k n a d därav, att sammansättningen innehäller en effektiv mängd av ett hydroxamsyraderivat enligt 35 patentkrav 1, att användas som medioin för förhindrande av MMP i däggdjur som en enda eller en flerfaldig dos tillsammans med en bärare.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90397597A | 1997-07-31 | 1997-07-31 | |
US90397597 | 1997-07-31 | ||
PCT/US1998/015868 WO1999006041A1 (en) | 1997-07-31 | 1998-07-30 | SUBSTITUTED ALKANOHYDROXAMIC ACIDS AND METHOD OF REDUCING TNFα LEVELS |
US9815868 | 1998-07-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
FI20000061A FI20000061A (sv) | 2000-03-02 |
FI119841B true FI119841B (sv) | 2009-04-15 |
Family
ID=25418328
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI20000061A FI119841B (sv) | 1997-07-31 | 2000-01-12 | Substituerade alkanohydroxamsyror och förfarande för sänkande av TNF alfa nivåer |
Country Status (20)
Country | Link |
---|---|
US (3) | US6214857B1 (sv) |
EP (1) | EP1035848B1 (sv) |
JP (1) | JP2001511448A (sv) |
KR (1) | KR100716475B1 (sv) |
CN (1) | CN1265590A (sv) |
AT (1) | ATE238052T1 (sv) |
AU (1) | AU737008B2 (sv) |
BR (1) | BR9815895A (sv) |
CA (1) | CA2295295A1 (sv) |
CZ (1) | CZ299873B6 (sv) |
DE (1) | DE69813876T2 (sv) |
ES (1) | ES2196592T3 (sv) |
FI (1) | FI119841B (sv) |
HU (1) | HUP0003761A3 (sv) |
NO (1) | NO315043B1 (sv) |
NZ (1) | NZ502379A (sv) |
PT (1) | PT1035848E (sv) |
RU (1) | RU2199530C2 (sv) |
TR (1) | TR200000221T2 (sv) |
WO (1) | WO1999006041A1 (sv) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6429221B1 (en) * | 1994-12-30 | 2002-08-06 | Celgene Corporation | Substituted imides |
US6518281B2 (en) * | 1995-08-29 | 2003-02-11 | Celgene Corporation | Immunotherapeutic agents |
CZ299810B6 (cs) * | 1996-08-12 | 2008-12-03 | Celgene Corporation | Substituovaná aromatická sloucenina a její použití pro snížení hladiny cytokinu |
CZ299873B6 (cs) | 1997-07-31 | 2008-12-17 | Celgene Corporation | Derivát hydroxamové kyseliny a farmaceutický prostredek s jeho obsahem |
EP1054877A1 (en) * | 1998-02-11 | 2000-11-29 | Du Pont Pharmaceuticals Company | Novel cyclic sulfonamide derivatives as metalloproteinase inhibitors |
US7629360B2 (en) * | 1999-05-07 | 2009-12-08 | Celgene Corporation | Methods for the treatment of cachexia and graft v. host disease |
US6667316B1 (en) * | 1999-11-12 | 2003-12-23 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
US6808902B1 (en) | 1999-11-12 | 2004-10-26 | Amgen Inc. | Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules |
US7182953B2 (en) | 1999-12-15 | 2007-02-27 | Celgene Corporation | Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
US6699899B1 (en) * | 1999-12-21 | 2004-03-02 | Celgene Corporation | Substituted acylhydroxamic acids and method of reducing TNFα levels |
US8030343B2 (en) | 2000-06-08 | 2011-10-04 | Celgene Corporation | Pharmaceutically active isoindoline derivatives |
US7091353B2 (en) * | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
MXPA04000134A (es) | 2001-06-26 | 2005-06-06 | Abgenix Inc | Anticuerpos para ligandos de osteoprotegerina. |
US6962940B2 (en) | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
US7276529B2 (en) | 2002-03-20 | 2007-10-02 | Celgene Corporation | Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
US7208516B2 (en) | 2002-03-20 | 2007-04-24 | Celgene Corporation | Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione |
US7893101B2 (en) | 2002-03-20 | 2011-02-22 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
US20050148034A1 (en) | 2002-04-12 | 2005-07-07 | Hariri Robert J. | Methods for identification of modulators of angiogenesis, compounds discovered thereby, and methods of treatment using the compounds |
EP1556033A4 (en) | 2002-05-17 | 2006-05-31 | Celgene Corp | METHODS AND COMPOSITIONS USING CYTOKINE INHIBITOR SELECTIVE MEDICAMENTS FOR THE TREATMENT AND MANAGEMENT OF CANCERS AND OTHER DISEASES |
US20100129363A1 (en) * | 2002-05-17 | 2010-05-27 | Zeldis Jerome B | Methods and compositions using pde4 inhibitors for the treatment and management of cancers |
AU2003250482A1 (en) * | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Phthalimide derivatives as matrix metalloproteinase inhibitors |
CA2501936A1 (en) * | 2002-10-15 | 2004-04-29 | Celgene Corporation | Selective cytokine inhibitory drugs for treating myelodysplastic syndrome |
US20050203142A1 (en) * | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
US20040087558A1 (en) | 2002-10-24 | 2004-05-06 | Zeldis Jerome B. | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
WO2004041181A2 (en) * | 2002-10-31 | 2004-05-21 | Celgene Corporation | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration |
US7776907B2 (en) * | 2002-10-31 | 2010-08-17 | Celgene Corporation | Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide |
MXPA05004777A (es) * | 2002-11-06 | 2005-07-22 | Celgene Corp | Metodos de uso y composiciones que comprenden farmacos inhibidores selectivos de citocina para el tratamiento y el manejo de padecimientos mieloproliferativos. |
CN1735412A (zh) | 2002-11-06 | 2006-02-15 | 细胞基因公司 | 利用选择性细胞因子抑制药物治疗和控制癌症和其它疾病的方法和组合物 |
BR0316256A (pt) * | 2002-11-18 | 2005-10-04 | Celgene Corp | Métodos de inibir a produção de tnf-alfa e a atividade de pde4, de tratar ou prevenir uma doença ou um distúrbio, de controlar os nìveis de camp em uma célula e de produzir um composto, composição farmacêutica e composto |
AU2003294311B8 (en) * | 2002-11-18 | 2008-06-05 | Celgene Corporation | Method of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide |
CA2511843C (en) * | 2002-12-30 | 2012-04-24 | Celgene Corporation | Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses |
US20040175382A1 (en) * | 2003-03-06 | 2004-09-09 | Schafer Peter H. | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
KR100831545B1 (ko) * | 2003-03-06 | 2008-05-21 | 셀진 코포레이션 | 중추 신경계 장애의 치료 또는 관리를 위한 선택적사이토카인 억제 약물의 사용 방법 및 그를 포함하는조성물 |
NZ542671A (en) * | 2003-03-12 | 2008-12-24 | Celgene Corp | 7-Amido-isoindolyl compounds and their pharmaceutical uses |
WO2004080422A2 (en) * | 2003-03-12 | 2004-09-23 | Celgene Corporation | N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses |
CN100427465C (zh) * | 2003-03-12 | 2008-10-22 | 细胞基因公司 | N-烷基-异羟肟酸-异吲哚基化合物及其药物用途 |
US7320992B2 (en) | 2003-08-25 | 2008-01-22 | Amgen Inc. | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use |
DE10340739A1 (de) * | 2003-09-04 | 2005-04-07 | Satia Gmbh | Verfahren zur enzymatischen Herstellung von Mono- und Diacylglycerid-haltigen Emulgatoren |
JP2007524656A (ja) * | 2003-10-23 | 2007-08-30 | セルジーン・コーポレーション | 疼痛を治療、改変および管理するための選択的サイトカイン阻害薬を含む組成物ならびにその使用方法 |
US20050142104A1 (en) * | 2003-11-06 | 2005-06-30 | Zeldis Jerome B. | Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders |
BRPI0418743A (pt) * | 2004-04-14 | 2007-09-18 | Celgene Corp | métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit |
CA2563377A1 (en) * | 2004-04-23 | 2005-11-03 | Celgene Corporation | Methods of using and compositions comprising pde4 modulators for the treatment and management of pulmonary hypertension |
US20080267905A1 (en) * | 2004-05-05 | 2008-10-30 | Celgene Corporation | Methods and Compositions Using Selective Cytokine Inhibitory Drugs for Treatment and Management of Cancers and Other Diseases |
CN1984652A (zh) * | 2004-05-05 | 2007-06-20 | 细胞基因公司 | 使用选择性细胞因子抑制药治疗和控制骨髓增生性疾病的方法和组合物 |
US7405237B2 (en) | 2004-07-28 | 2008-07-29 | Celgene Corporation | Isoindoline compounds and methods of their use |
US20070190070A1 (en) * | 2004-09-03 | 2007-08-16 | Zeldis Jerome B | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
JP2008518924A (ja) * | 2004-10-28 | 2008-06-05 | セルジーン・コーポレーション | 中枢神経系損傷の治療及び管理のためのpde4モジュレータを使用する方法及び組成物 |
US20080138295A1 (en) * | 2005-09-12 | 2008-06-12 | Celgene Coporation | Bechet's disease using cyclopropyl-N-carboxamide |
AR059898A1 (es) | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
AU2007281591A1 (en) | 2006-07-31 | 2008-02-07 | Janssen Pharmaceutica, N.V. | Urotensin II receptor antagonists |
TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
PA8782701A1 (es) | 2007-06-07 | 2009-01-23 | Janssen Pharmaceutica Nv | Antagonistas del receptor de urotensina ii |
PT2203439E (pt) | 2007-09-14 | 2011-02-11 | Ortho Mcneil Janssen Pharm | 4-fenil-3,4,5,6-tetra-hidro-2h,1'h-[1,4']bipiridinil-2'- onas 1',3'-dissubstituídas |
US9079896B2 (en) * | 2008-08-02 | 2015-07-14 | Janssen Pharmaceutica Nv | Urotensin II receptor antagonists |
BRPI0918055A2 (pt) | 2008-09-02 | 2015-12-01 | Addex Pharmaceuticals Sa | derivados de 3-azabiciclo[3,1,0]hexila como moduladores de receptores metabotrópicos de glutamato. |
JP5690277B2 (ja) | 2008-11-28 | 2015-03-25 | ジャンセン ファーマシューティカルズ, インコーポレイテッド. | 代謝型グルタミン酸受容体の調節因子としてのインドールおよびベンゾオキサジン誘導体 |
MY160002A (en) | 2009-02-10 | 2017-02-15 | Celgene Corp | Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis |
NZ596078A (en) | 2009-05-12 | 2013-06-28 | Janssen Pharmaceuticals Inc | 1,2,4-TRIAZOLO [4,3-a] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS |
CN102439015B (zh) | 2009-05-12 | 2015-05-13 | 杨森制药有限公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物和其作为mGluR2受体的正向变构调节剂的用途 |
MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
MX341050B (es) | 2010-04-07 | 2016-08-05 | Celgene Corp * | Metodos para tratar infeccion viral respiratoria. |
MX341896B (es) | 2010-06-15 | 2016-09-07 | Celgene Corp * | Biomarcadores para el tratamiento de psoriasis. |
US8993591B2 (en) | 2010-11-08 | 2015-03-31 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors |
CA2814998C (en) | 2010-11-08 | 2019-10-29 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
US9271967B2 (en) | 2010-11-08 | 2016-03-01 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
CN102993153B (zh) * | 2012-12-29 | 2015-05-13 | 吉首大学 | 异黄酮-n-甲基氧肟酸类尿素酶抑制剂及其合成和用途 |
CN102976974B (zh) * | 2012-12-29 | 2015-01-21 | 吉首大学 | 苯基苄基丙酰-n-甲基氧肟酸类尿素酶抑制剂及其合成和用途 |
CN102993152B (zh) * | 2012-12-29 | 2015-04-01 | 吉首大学 | 尿素酶抑制剂异黄酮氧肟酸化合物及其合成和用途 |
JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
ME03518B (me) | 2014-01-21 | 2020-04-20 | Janssen Pharmaceutica Nv | Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena |
SI3096790T1 (sl) | 2014-01-21 | 2019-11-29 | Janssen Pharmaceutica Nv | Kombinacije, ki vsebujejo pozitivne aleostrične modulatorje ali ortosterične agoniste metabotropnega glutamatergičnega receptorja podtipa 2 in njihova uporaba |
US20170087129A1 (en) | 2014-05-16 | 2017-03-30 | Celgene Corporation | Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators |
US10300042B2 (en) | 2014-06-23 | 2019-05-28 | Celgene Corporation | Apremilast for the treatment of a liver disease or a liver function abnormality |
US10011611B2 (en) | 2015-08-14 | 2018-07-03 | Reaction Biology Corp. | Histone deacetylase inhibitors and methods for use thereof |
US10682336B2 (en) | 2015-10-21 | 2020-06-16 | Amgen Inc. | PDE4 modulators for treating and preventing immune reconstitution inflammatory syndrome (IRIS) |
KR102445637B1 (ko) * | 2017-11-28 | 2022-09-22 | 솔브레인 주식회사 | 레벨링제 및 이를 포함하는 전기도금 조성물 |
WO2019201255A1 (zh) * | 2018-04-17 | 2019-10-24 | 天津合美医药科技有限公司 | 异吲哚衍生物 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4077998A (en) * | 1975-10-28 | 1978-03-07 | Morton-Norwich Products, Inc. | Phthaloyl amino acid hydroxamic acids |
US4173652A (en) | 1976-12-18 | 1979-11-06 | Akzona Incorporated | Pharmaceutical hydroxamic acid compositions and uses thereof |
US4820828A (en) | 1987-03-04 | 1989-04-11 | Ortho Pharmaceutical Corporation | Cinnamohydroxamic acids |
US5463063A (en) * | 1993-07-02 | 1995-10-31 | Celgene Corporation | Ring closure of N-phthaloylglutamines |
US5605914A (en) * | 1993-07-02 | 1997-02-25 | Celgene Corporation | Imides |
CA2227237C (en) | 1995-07-26 | 2005-12-13 | Pfizer Inc. | N-(aroyl)glycine hydroxamic acid derivatives and related compounds |
CZ299873B6 (cs) * | 1997-07-31 | 2008-12-17 | Celgene Corporation | Derivát hydroxamové kyseliny a farmaceutický prostredek s jeho obsahem |
-
1998
- 1998-07-30 CZ CZ20000256A patent/CZ299873B6/cs not_active IP Right Cessation
- 1998-07-30 KR KR1020007001011A patent/KR100716475B1/ko not_active IP Right Cessation
- 1998-07-30 AU AU86741/98A patent/AU737008B2/en not_active Ceased
- 1998-07-30 CN CN98807775A patent/CN1265590A/zh active Pending
- 1998-07-30 EP EP98938151A patent/EP1035848B1/en not_active Expired - Lifetime
- 1998-07-30 JP JP2000504855A patent/JP2001511448A/ja active Pending
- 1998-07-30 DE DE69813876T patent/DE69813876T2/de not_active Expired - Fee Related
- 1998-07-30 TR TR2000/00221T patent/TR200000221T2/xx unknown
- 1998-07-30 PT PT98938151T patent/PT1035848E/pt unknown
- 1998-07-30 BR BR9815895-3A patent/BR9815895A/pt not_active Application Discontinuation
- 1998-07-30 HU HU0003761A patent/HUP0003761A3/hu unknown
- 1998-07-30 AT AT98938151T patent/ATE238052T1/de not_active IP Right Cessation
- 1998-07-30 CA CA002295295A patent/CA2295295A1/en not_active Abandoned
- 1998-07-30 NZ NZ502379A patent/NZ502379A/xx unknown
- 1998-07-30 WO PCT/US1998/015868 patent/WO1999006041A1/en active IP Right Grant
- 1998-07-30 RU RU2000102639/04A patent/RU2199530C2/ru not_active IP Right Cessation
- 1998-07-30 US US09/126,157 patent/US6214857B1/en not_active Expired - Fee Related
- 1998-07-30 ES ES98938151T patent/ES2196592T3/es not_active Expired - Lifetime
-
1999
- 1999-12-28 NO NO19996529A patent/NO315043B1/no not_active IP Right Cessation
-
2000
- 2000-01-12 FI FI20000061A patent/FI119841B/sv active IP Right Grant
-
2001
- 2001-02-09 US US09/780,725 patent/US6656964B2/en not_active Expired - Fee Related
-
2003
- 2003-06-16 US US10/462,319 patent/US7091356B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
AU737008B2 (en) | 2001-08-09 |
US20040006096A1 (en) | 2004-01-08 |
AU8674198A (en) | 1999-02-22 |
EP1035848B1 (en) | 2003-04-23 |
EP1035848A4 (en) | 2001-05-23 |
PT1035848E (pt) | 2003-09-30 |
NO996529L (no) | 2000-03-28 |
US20010049371A1 (en) | 2001-12-06 |
KR20010022429A (ko) | 2001-03-15 |
CA2295295A1 (en) | 1999-02-11 |
ES2196592T3 (es) | 2003-12-16 |
EP1035848A1 (en) | 2000-09-20 |
TR200000221T2 (tr) | 2000-09-21 |
ATE238052T1 (de) | 2003-05-15 |
HUP0003761A2 (en) | 2001-03-28 |
US6656964B2 (en) | 2003-12-02 |
NZ502379A (en) | 2002-10-25 |
WO1999006041A1 (en) | 1999-02-11 |
JP2001511448A (ja) | 2001-08-14 |
NO996529D0 (no) | 1999-12-28 |
US6214857B1 (en) | 2001-04-10 |
CZ299873B6 (cs) | 2008-12-17 |
NO315043B1 (no) | 2003-06-30 |
CN1265590A (zh) | 2000-09-06 |
HUP0003761A3 (en) | 2001-04-28 |
BR9815895A (pt) | 2001-01-16 |
KR100716475B1 (ko) | 2007-05-10 |
RU2199530C2 (ru) | 2003-02-27 |
CZ2000256A3 (cs) | 2000-06-14 |
US7091356B2 (en) | 2006-08-15 |
FI20000061A (sv) | 2000-03-02 |
DE69813876T2 (de) | 2004-01-29 |
DE69813876D1 (de) | 2003-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI119841B (sv) | Substituerade alkanohydroxamsyror och förfarande för sänkande av TNF alfa nivåer | |
US6699899B1 (en) | Substituted acylhydroxamic acids and method of reducing TNFα levels | |
FI121708B (sv) | Substituerade 1,3,4-oxadiazoler | |
HU226558B1 (en) | Immunotherapeutic imides/amides and their use for reducing levels of tnfalpha | |
KR100614216B1 (ko) | 치환된 알카노하이드록삼산을 유효성분으로 함유하는약학적 조성물 | |
MXPA00001018A (es) | Acidos alcanohidroxamicos sustituidos y metodos para reducir niveles de tnf alfa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Patent granted |
Ref document number: 119841 Country of ref document: FI |